AL amyloidosis is a clonal plasma cell dyscrasia in which misfolded immunoglobulin light chains deposit in tissues and produce organ failure and death. Untreated, median survival is short. Melphalan-based regimens can produce hematologic remissions and improvement in organ function; more than 20% of patients treated with high dose melphalan and autologous stem cell transplantation (HDM/SCT) have survived more than 10 years (Blood, in press). The combination of lenalidomide and dexamethasone can also produce partial and complete hematologic responses (
Disclosure:Research Funding: Support for drug and costs of clinical trial. Honoraria Information: Honorarium for one day visit to discuss next clinical trial ($1000 or less). Off Label Use: Use of an approved drug (lenalidomide) for an off-label indication (amyloidosis).